Dr. Song is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
NKGen Biotech
3001 Daimler St
Santa Ana, CA 92705Phone+1 310-310-1992
Summary
- I am a board certified radiation oncologist and biotech executive.
Education & Training
- University of Chicago/University of Illinois College of Medicine at ChicagoResidency, Radiation Oncology, 1992 - 1996
- St Barnabas Medical CenterInternship, Transitional Year, 1991 - 1992
- George Washington University School of Medicine and Health SciencesClass of 1991
Certifications & Licensure
- CA State Medical License 2007 - 2026
- IL State Medical License 1992 - 2014
- NV State Medical License 2005 - 2009
- VA State Medical License 1996 - 2008
- SC State Medical License 1995 - 1996
- American Board of Radiology Radiation Oncology
Clinical Trials
- Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Start of enrollment: 2019 Jul 15
Publications & Presentations
PubMed
- 4 citationsManagement of radiation-induced mucosal necrosis with photobiomodulation therapy.Joel B. Epstein, Paul Y. Song, Allen S. Ho, Babak Larian, Arash Asher
Supportive Care in Cancer. 2018-05-04 - 7 citationsPhotobiomodulation therapy: management of mucosal necrosis of the oropharynx in previously treated head and neck cancer patientsJoel B. Epstein, Paul Y. Song, Allen S. Ho, Babak Larian, Arash Asher
Supportive Care in Cancer. 2017-04-01 - 34 citationsSelf-assessed health-related quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient-assessed bot...William Dale, Timothy Campbell, Lani Ignacio, Paul Y. Song, Mitchell Kopnick
Urology. 1999-02-01
Press Mentions
- NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024June 12th, 2024
- Phase 1/2a Trial of NK Cell Therapy SNK01 Wins FDA ClearanceMay 8th, 2024
- NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 25th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: